VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
We catch up with the runner-up in our Parkinson's poetry competition
1 week ago
Queen Elizabeth II honours UK university for Parkinson’s research
A neuroscience research centre at the University of Sheffield, UK, has been recognised by Queen Elizabeth II for improving the lives of patients living with neurodegenerative conditions, including Parkinson’s. The Sheffield Institute for Translational Neuroscience, which is based at the university, uses emerging developments in neuroscience to create innovative new approaches to treating brain conditions. The prestigious Queen’s Anniversary Prize was awarded at St James’s Palace, London. The institute was commended for its development of Parkinson’s drug discovery programmes. The honour is awarded to UK universities who exhibit groundbreaking and innovative approaches to research – with beneficial results at local, national and global levels. Professor Koen Lamberts, president and vice-chancellor for the University of Sheffield, said: “As well as making life-changing discoveries today, The Sheffield Institute for Translational Neuroscience is nurturing the next generation of talented neuroscience students, whose research will lead to pioneering treatments for those living with neurological…
Researchers at Helsinki University Hospital, Finland, have found that the overuse of antibiotic drugs could increase the risk of developing Parkinson’s. The study – published in medical journal ‘Movement Disorders’ – compared data on antibiotic exposure in 13,976 people with Parkinson’s and 40,697 people without. The researchers found that overuse of some antibiotic drugs can cause Parkinson’s, that it can take up to 15 years before any symptoms emerge – and that the connection to Parkinson’s could be due to the drug’s effects on the gut. Filip Scheperjans, neurologist and lead researcher of the study, said: “The link between antibiotic exposure and Parkinson’s disease fits the current view that in a significant proportion of patients the pathology of Parkinson’s may originate in the gut, possibly related to microbial changes, years before the onset of typical Parkinson’s symptoms such as slowness, muscle stiffness and shaking of the extremities.”
New Parkinson’s health app to track symptoms more accurately
Health app SleepFit could be used to track Parkinson’s symptoms in real time, providing clinicians with a more accurate view of patients’ condition, according to a new study. As part of the research – published in ‘Journal of Parkinson’s Disease’ – 42 people with Parkinson’s recorded their symptoms on the app four times a day for a period of two weeks. After the study, to test the data against patients’ own recollection of their symptoms, those participating completed a questionnaire – recording symptoms such as walking difficulty and hand dexterity. The results showed that 16.7% of those who took part tended to over or underestimate their symptoms when completing the questionnaire, therefore providing inaccurate information. Dr Pietro Luca Ratti, lead researcher of the study, said: “The importance of accurately assessing motor symptoms is pivotal in the clinical follow-up of patients with Parkinson’s Disease.”